Work

1668TiP Phase Ib study of AMG 757, a half-life extended bispecific T-cell engager immuno-oncology therapy, combined with AMG 404, an anti-PD-1 antibody, in patients with small cell lung cancer (SCLC)

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.252

Authors: A. Dowlati, L.A. Byers, M.L. Johnson, R. Aljumaily, H. Prenen, A. Zhang, M. Minocha, A. Shetty, N. Hashemi Sadraei

Institutions: University Hospitals Seidman Cancer Center, Case Western Reserve University, The University of Texas MD Anderson Cancer Center, Sarah Cannon, Tennessee Oncology, OU Health Stephenson Cancer Center, University of Oklahoma, Antwerp University Hospital, Amgen (United States)

Language: English

Topic: Lung Cancer Research Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3203334985

FWCI: 0.328

Cites:

Cited by: 4

Related to: 10